Literature DB >> 8373187

Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: catalytic properties and interaction with antifolates.

S A Margosiak1, J R Appleman, D V Santi, R L Blakley.   

Abstract

Dihydrofolate reductase (DHFR) from the fungus Pneumocystis carinii (pcDHFR), a target for antifolate inhibitors, has been compared with host enzyme, human DHFR (hDHFR), and with DHFR from Escherichia coli. Among the results of the considerable structural differences between pcDHFR and the other two enzymes is a much higher turnover number (kcat, 136 s-1) for pcDHFR. This is due to rapid hydride transfer from NADPH to dihydrofolate (rate constant 402 s-1), very rapid dissociation of NADP from the product complex (rate constant, k(off), > 1000 s-1), and after NADPH binding, rapid dissociation of tetrahydrofolate (k(off), 216 s-1). Cycling of pcDHFR is almost exclusively by this pathway. The high kcat contributes to a high Km for NADPH (9 microM) and an unusually high Km for dihydrofolate (2.5 microM). Nevertheless, the efficiency of pcDHFR is greater than DHFR from E. coli and about 25% that of hDHFR. Of seven clinically relevant inhibitors investigated, only one (trimethoprim) had a slightly lower Ki for pcDHFR than for hDHFR. The therapeutic value of trimethoprim-sulfa treatment of P. carinii infections indicates that other factors play an important role, but the results are consistent with the frequency of complications due to toxicity of trimethoprim.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373187     DOI: 10.1006/abbi.1993.1453

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Novel crystallization conditions for tandem variant R67 DHFR yield a wild-type crystal structure.

Authors:  Brahm J Yachnin; Damien Y Colin; Jordan P Volpato; Maximilian Ebert; Joelle N Pelletier; Albert M Berghuis
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-10-25

2.  Two parallel pathways in the kinetic sequence of the dihydrofolate reductase from Mycobacterium tuberculosis.

Authors:  Clarissa M Czekster; An Vandemeulebroucke; John S Blanchard
Journal:  Biochemistry       Date:  2011-07-22       Impact factor: 3.162

3.  Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Authors:  Y Wang; J A Bruenn; S F Queener; V Cody
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii.

Authors:  S F Queener; V Cody; J Pace; P Torkelson; A Gangjee
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

7.  Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.

Authors:  Yu-Shan Cheng; James C Sacchettini
Journal:  Biochemistry       Date:  2016-02-05       Impact factor: 3.162

8.  Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase.

Authors:  Marc W Gibson; Simon Dewar; Han B Ong; Natasha Sienkiewicz; Alan H Fairlamb
Journal:  PLoS Negl Trop Dis       Date:  2016-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.